Ensysce Biosciences Inc (ENSC) — Cash Flow-to-Debt Ratio
Ensysce Biosciences Inc (ENSC) has a Cash Flow-to-Debt Ratio of -1.23x as of March 2026, meaning its operating cash flow of $-3.50 Million could theoretically repay -1% of its total liabilities ($2.84 Million) in one year. Check Ensysce Biosciences Inc (ENSC) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Ensysce Biosciences Inc Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Ensysce Biosciences Inc across 9 annual periods. Also explore Ensysce Biosciences Inc asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Ensysce Biosciences Inc (2017–2025)
Year-by-year debt coverage analysis for Ensysce Biosciences Inc. For market capitalisation and broader financial context, see Ensysce Biosciences Inc (ENSC) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1709009.44x | $-7.81 Trillion | $4.57 Million | ▲ +49.5% |
| 2024 | -3383720.60x | $-7.50 Trillion | $2.22 Million | ▼ -105446352.2% |
| 2023 | -3.21x | $-10.78 Million | $3.36 Million | ▼ -77.9% |
| 2022 | -1.80x | $-17.89 Million | $9.91 Million | ▼ -437.9% |
| 2021 | -0.34x | $-8.24 Million | $24.58 Million | ▼ -88.5% |
| 2020 | -0.18x | $-1.25 Million | $7.01 Million | ▼ -116.7% |
| 2019 | 1.06x | $10.99 Million | $10.34 Million | ▲ +739.0% |
| 2018 | -0.17x | $-1.24 Million | $7.44 Million | ▼ -373.0% |
| 2017 | -0.04x | $-251.83K | $7.16 Million | — |